Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


InterMune's Esbriet gets OK from EU CHMP: launch expected 3Q11

This article was originally published in Scrip

Executive Summary

InterMune's Esbriet (pirfenidone) received a positive opinion by the EU's Committee for Medicinal Products for Human Use (CHMP), the first European approval for any drug to treat mild-to-moderate idiopathic pulmonary fibrosis (IPF). In a conference call, the company CEO and President, Dan Welch, said that the company anticipated a price band for the product of $40,000-45,000 and that the product would be launched in the five largest European national markets – Germany, France, Italy, Spain and the UK – by mid 2012, with the first launch in Germany scheduled for the third quarter of 2011.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts